Celularity Inc. Receivables, Fair Value Disclosure
Celularity Inc. (CELU) had Receivables, Fair Value Disclosure of $1.41 million as of 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:ReceivablesFairValueDisclosure · last filed 2026-04-30
- 2025-12-31: Receivables, Fair Value Disclosure $1.41M.
- 2025-09-30: Receivables, Fair Value Disclosure $1.41M.
- 2025-06-30: Receivables, Fair Value Disclosure $1.41M.
- 2025-03-31: Receivables, Fair Value Disclosure $1.41M.
| Period end | Receivables, Fair Value Disclosure | Receivables, Fair Value Disclosure as first filed |
|---|---|---|
| 2025-12-31 | $1.41M 10-K · filed 2026-04-30 | |
| 2025-09-30 | $1.41M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $1.41M 10-Q · filed 2025-08-29 | |
| 2025-03-31 | $1.41M 10-Q · filed 2025-08-29 | |
| 2024-12-31 | $1.41M 10-K · filed 2026-04-30 | |
| 2023-12-31 | $1.61M 10-K · filed 2026-04-30 | $2.07M 10-K · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |